Abstract
Background: The expression of epidermal growth factor receptor (EGF-R) in breast cancer (BC) is generally considered as an unfavorable event during tumor progression. Its predictive role has been fairly well defined: EGF-R expression predicts tamoxifen unresponsiveness. EGF-R role in autocrine growth regulation was confirmed. However, reported results on its prognostic role in BC patients were conflicting. The prognostic role of EGF-R after 15 years of follow-up is analyzed in a group of 70 localized BC patients, presented at diagnosis in clinical stages I-III. Methods: BC patients newly diagnosed from December 1990 until March 1991, treated in accordance to the National Protocol, were selected for EGF-R analysis. Steroid receptors and EGF-R were determined at diagnosis in same frozen tissue samples, using biochemical methods. Except 6 patients who were lost from follow-up in the interval shorter than 60 months, the remaining patients were followed-up from 60-188 months. The total number of events was 32 relapses (46%), and 27 deaths (38.5%). Results: EGF-R expression was found in 28/70 patients (40%), and the EGF-R content higher than 26 fmol - in 15/70 patients (21%). Neither the expression, nor the high content of EGF-R showed any influence on disease-free or overall survival. Levels of EGF-R were similar in relapsing and relapse-free patients. Nodal status had the strongest infuence on prognosis. Conclusion: Our results suggest that the controversial findings, regarding the EGF-R prognostic role, might be the consequence of a genuine weak influence of EGF-R expression on disease outcome. .
Highlights
Epidermal growth factor receptor (EGF-R), a member of large type I receptor family, is a membrane protein, which binds ligands, such as EGF or transforming growth factor-A (TGF-A), with the extra cellular region, containing ligand binding domain
We found that the epidermal growth factor receptor (EGF-R) values mostly were overlapped between responders and non-respondHUV EXW GLG QHYHU H[FHHG IPROPJ LQ WKRVH WXPRUV WKDW KDG UHJUHVVHG RQ HQGRFULQH WKHUDS\/DWHULWZDVUHSRUWHGWKDWWKH(*)5 DQGRU+(5 H[SUHVVLQJWXPRUVVHHPHGWR be less responsive to tamoxifen, but not to aromatase inhibitors [11], which suggested the role of EGF-R in clinical resistance to tamoxifen
In accordance with the EGF-R role in endocrine- resistance and autocrine tumor growth regulation, it was expected that the prognosis would be much poorer in patients with EGF-R expressing tumors
Summary
Epidermal growth factor receptor (EGF-R), a member of large type I receptor family, is a membrane protein, which binds ligands, such as EGF or transforming growth factor-A (TGF-A), with the extra cellular region, containing ligand binding domain. In accordance with the EGF-R role in endocrine- (tamoxifen-) resistance and autocrine tumor growth regulation, it was expected that the prognosis would be much poorer in patients with EGF-R expressing tumors. Harris and co-workers [13] found that the EGF-R-expressing operable breast cancer patients had shorter DFI and OS.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
